TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33480963
Drug: Margetuximab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margetuximab (15 mg/kg) plus chemotherapy
Study: 33480963
Drug: Trastuzumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (6 mg/kg, loading dose 8 mg/kg) plus chemotherapy
Study: 34907910
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus cobimetinib (combination arm)
Study: 34907910
Drug: Atezolizumab monotherapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab monotherapy (monotherapy arm)
Study: 32941462
Drug: Proactive electronic-consultation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive electronic-consultation from pulmonologists recommending ICS discontinuation
Study: 32941462
Drug: Unexposed providers'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unexposed providers' anticipation of patient resistance to ICS discontinuation
Study: 33836161
Drug: Benznidazole 300
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 300 mg daily for 8 weeks
Study: 33836161
Drug: Benznidazole 300
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 300 mg daily for 4 weeks
Study: 33836161
Drug: Benznidazole 300
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 300 mg daily for 2 weeks
Study: 33836161
Drug: Benznidazole 150
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 150 mg daily for 4 weeks
Study: 33836161
Drug: Benznidazole 150
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 150 mg daily for 4 weeks plus fosravuconazole
Study: 33836161
Drug: Benznidazole 300
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole 300 mg weekly for 8 weeks plus fosravuconazole
Study: 616864697
Drug: Mannatide, oxaliplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannatide, oxaliplatin, and docetaxel sequential therapy
Study: 616864697
Drug: Thymosin, oxaliplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin, oxaliplatin, and docetaxel sequential therapy
Study: 34526081
Drug: Raw natural
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw natural honey (0.5 g) and encapsulated organic Nigella sativa seeds (40 mg) per kg body weight per day
Study: 34526081
Drug: Placebo (empty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (empty capsule with 30 ml of 5% dextrose water)
Study: 36206399
Drug: Therapy duration
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy duration >= 1 year
Study: 32282564
Drug: Acupressure on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure on 6 acupoints administered at home every night for 4 weeks
Study: 32282564
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group maintained their daily routine
Study: 34781981
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg daily for the first four days, then 400 mg weekly)
Study: 34781981
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same treatment schedule as hydroxychloroquine)
Study: 33579340
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (neoadjuvant radiotherapy + surgery)
Study: 33749976
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to biological metrics of Life's Simple 7 (LS7)
Study: 32221084
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine combined with western medicine (ESWL treatment and TCM therapy)
Study: 32221084
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment (control group)
Study: 34985309
Drug: Standard-dose DOAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose DOAC
Study: 34985309
Drug: Lower-dose DOAC
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose DOAC
Study: 33528930
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy with allergens (SCITA)
Study: 35435087
Drug: Plasma gel
Normalized name: Plasma gelsolin
DrugBank: Recombinant human plasma gelsolin (DB15746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma gel
Study: 35435087
Drug: Control (Plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Plasma gel vs Plasma fluid)
Study: 32758407
Drug: Sternotomy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sternotomy group (15 patients) received 0.25% bupivacaine subcutaneous infiltration.
Study: 32758407
Drug: Thoracotomy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracotomy group (15 patients) with 11 receiving fascial plane block and 3 receiving subcutaneous infiltration.
Study: 33049433
Drug: Clinical judgment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical judgment (recommended treatment)
Study: 34874888
Drug: blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: blended cognitive behavioral therapy (bCBT)
Study: 33191157
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation by a pharmacy team
Study: 33216238
Drug: Sufentanil sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil sublingual tablet system (SSTS)
Study: 35611515
Drug: Additional antiemetic
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional antiemetic drug use
Study: 33110039
Drug: E2/P4 1/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/P4 1/100 mg/mg
Study: 33110039
Drug: E2/P4 0.5/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/P4 0.5/100 mg/mg
Study: 33215755
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants with a provisional fixed prosthesis
Study: 34144359
Drug: No surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surface treatment (CTRL)
Study: 35150243
Drug: Dopamine D2/D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2/D3 receptor availability
Study: 36017827
Drug: Multi-day rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Multi-day rivastigmine transdermal patch (RID-TDS), applied on a 4-3-4 day regimen for 11 consecutive days.
Study: 36017827
Drug: Exelon® transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exelon® transdermal patch, applied daily for 11 consecutive days.
Study: 34758251
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase followed by EVT
Study: 32320401
Drug: Febuxostat (10-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (10-60 mg daily)
Study: 34821978
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral hygiene motivation only)
Study: 32147225
Drug: 900 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 μg salbutamol
Study: 33973551
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (three cycles of full-dose anthracycline and ifosfamide)
Study: 33973551
Drug: Perioperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative systemic treatment
Study: 35275606
Drug: Diabetes patients
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes patients on insulin
Study: 35275606
Drug: Diabetes patients
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes patients not on insulin
Study: 34357396
Drug: 2-hour infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-hour infusion of Vasoactive Intestinal Polypeptide (VIP)
Study: 32331036
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray + oral antidepressant (ESK+AD)
Study: 32515747
Drug: Tablet app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet app-based dexterity training (TAD-MS) for 4 weeks, five times a week, 30 minutes per session.
Study: 32515747
Drug: Tablet app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet app-based dexterity training (TAD-MS)
Study: 35052995
Drug: Curasept Periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curasept Periodontal Gel (chlorhexidine-based)
Study: 32001213
Drug: Pooled non-control
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled non-control doses group
Study: 35738633
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m2 subcutaneously on days 1, 4, 8, and 11) and Pegylated Liposomal Doxorubicin (40 mg/m2 intravenously on day 4), every 4 weeks
Study: 32960539
Drug: Rectal biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal biopsy
Study: 32960539
Drug: Rectal swab
Normalized name: witch hazel .5 mL RECTAL SWAB [Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal swab
Study: 33559433
Drug: Shao's five-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shao's five-needle therapy combined with conventional western medical treatment
Study: 33559433
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medical treatment
Study: 34587385
Drug: Ozanimod (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod (1 mg once daily)
Study: 34850160
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg once-daily
Study: 35987996
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + esketamine 0.05 mg/kg (PK1 group)
Study: 35987996
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + esketamine 0.1 mg/kg (PK2 group)
Study: 35987996
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + esketamine 0.2 mg/kg (PK3 group)
Study: 32204780
Drug: Interventions aligned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventions aligned with the Occupational Therapy Practice Framework: Domain and Process (3rd ed.)
Study: 32204780
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (no specific occupational therapy intervention mentioned)
Study: 32350785
Drug: 4 units
Normalized name: Afrezza, 4 units inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 units of FFP administered before separation from CPB and 4 units of FFP and 20 units of platelet concentrate administered after separation from CPB
Study: 32350785
Drug: 8 units
Normalized name: Afrezza, 8 units inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 units of FFP and 20 units of platelet concentrate administered after separation from CPB
Study: 33780264
Drug: Icotinib combined
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib combined with concurrent chemoradiotherapy (CRT)
Study: 32778008
Drug: Low-iron formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-iron formula (2.3 mg/L)
Study: 37712908
Drug: Eculizumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab treatment
Study: 34649850
Drug: Peer‐driven intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer‐driven intervention for resuming CPAP use after discontinuation.
Study: 33830437
Drug: Metformin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (target dose 1000 mg bid)
Study: 32268991
Drug: Herbal compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal compound (500 mg of Plantago ovata husk in 30 mL water plus three drops of vinegar per dose, used as a mouthwash)
Study: 33239950
Drug: CHO-M (CHO-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-M (CHO-electrolyte solution + MBI)
Study: 33239950
Drug: Control (noncarbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (noncarbohydrate solution + traveling introduction audio)
Study: 33239950
Drug: CHO (Carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (Carbohydrate-electrolyte solution + traveling introduction audio)
Study: 35304299
Drug: Closed incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed incision negative pressure therapy (ciNPT) dressing for 7 days
Study: 33413353
Drug: VHA smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: VHA smoking cessation medication use
Study: 35382960
Drug: Medication disposal
Normalized name: MEDICATION DISPOSAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication disposal pouch
Study: 35315909
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy for 3 months
Study: 33561507
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (RT quality graded as per protocol - PP)
Study: 33561507
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (RT quality graded as minor deviation - MiD)
Study: 33561507
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (RT quality graded as major deviation - MaD)
Study: 32293527
Drug: Optimised vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimised vancomycin regimen (loading dose of 25 mg/kg followed by 15 mg/kg q12h or q8h for 5 ± 1 days)
Study: 32293527
Drug: Standard vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard vancomycin regimen (15 mg/kg q24h, q12h or q8h for 10 ± 2 days)
Study: 34215454
Drug: GBS-NN vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS-NN vaccine (100 µg adjuvanted)
Study: 34215454
Drug: GBS-NN vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS-NN vaccine (two doses of 50 µg adjuvanted)
Study: 34215454
Drug: GBS-NN vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS-NN vaccine (adjuvanted)
Study: 34215454
Drug: GBS-NN vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS-NN vaccine (two doses of 50 µg)
Study: 34933545
Drug: Alpha-blocker agents
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker agents
Study: 34321096
Drug: Epratuzumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab (monoclonal antibody targeting CD22)
Study: 35504550
Drug: Topical antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antiviral therapy (TAT)
Study: 35504550
Drug: Topical antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antiviral therapy + adjunctive antimicrobial photodynamic therapy (TAT + aPDT)
Study: 35288009
Drug: 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg carbohydrate (≤400 ml) 2 hours before surgery
Study: 34619044
Drug: CBD (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (300 mg daily for 14 days)
Study: 32574506
Drug: HBOT-EMI (Hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOT-EMI (Hyperbaric Oxygen Therapy and Exercise and Mental Imagery)
Study: 34375409
Drug: Text Messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text Messaging Intervention (TMI) - 174 automated text messages plus a group smoking counseling session and provision of nicotine patches
Study: 34569204
Drug: Acupoint application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint application of Chinese herbal medicine (Rhizome Pinelliae Preparata, Ginger, Clove) for 6 hours before anesthesia induction, changed after 24 hours, lasting for 2 days.
Study: 34569204
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received placebo plasters (flour and excipients with 10% of experimental drug concentration) for 6 hours before anesthesia induction, changed after 24 hours, lasting for 2 days.
Study: 35887701
Drug: Repetitive vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive vascular occlusion stimulus (RVOS) applied twice daily for 10 days (4 cycles of 5 min tourniquet inflation to 50 mmHg supra-systolic blood pressure, and 5 min complete deflation)
Study: 34237973
Drug: Irrigation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation and drainage device with irrigated antibiotics
Study: 39018512
Drug: Teriflunomide 14
Normalized name: teriflunomide 14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide 14 mg once daily
Study: 35565826
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of a lecithin‐based delivery form of Boswellia serrata (CASP) for 5 days
Study: 35565826
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of a lecithin‐based delivery form of Boswellia serrata (CASP)
Study: 33846036
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin therapy
Study: 33846036
Drug: Symptomatic care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic care and specific therapies (including intravenous aminophylline)
Study: 35865740
Drug: 3% Kānuka
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Kānuka oil cream
Study: 32965075
Drug: PEX168/100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEX168/100 μg
Study: 32965075
Drug: PEX168/200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEX168/200 μg
Study: 33606901
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop with faster-acting insulin aspart (Fiasp)
Study: 33606901
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop with standard insulin aspart
Study: 32894075
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose short-term memory program (placebo control)
Study: 32824483
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg AME
Study: 32824483
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg AME
Study: 32211767
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Cr/d from Cr Prop
Study: 32211767
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Cr/d from Cr Prop
Study: 32211767
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg Cr/d from Cr Prop
Study: 32211767
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg Cr/d from Cr Prop
Study: 32211767
Drug: 2 or
Normalized name: CP-2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 4 mg Cr/d from Cr Prop
Study: 35014110
Drug: High E2
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High E2 group (12 mg of E2 valerate)
Study: 34085585
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb761) at 200 μg/mL
Study: 35597370
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid supplementation to rescue therapy
Study: 34642949
Drug: ASP0367 (bocidelpar
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP0367 (bocidelpar sulfate) single doses of 1 to 120 mg
Study: 34642949
Drug: ASP0367 (bocidelpar
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP0367 (bocidelpar sulfate) multiple once-daily doses of 10 to 75 mg
Study: 36093695
Drug: Nichi Glucan
Normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nichi Glucan 0.5g twice daily along with conventional treatment for 90 days
Study: 36093695
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment comprising remedial behavioral therapies and L-carnosine 500 mg per day
Study: 36381204
Drug: Intra-sacroiliac joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-sacroiliac joint methylprednisolone injection (40 mg) plus NSAIDs and sulfasalazine (2 to 3 g/day)
Study: 36381204
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no methylprednisolone injection)
Study: 32145825
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cisplatin 70 mg/m2 or carboplatin AUC4.5/AUC5 for GFR <50 mL/min, plus gemcitabine 1000 mg/m2 on days 1 and 8)
Study: 33892269
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and Yoga